PubRank

Thomas Gasser

Author PubWeight™ 286.69‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004 14.35
2 Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009 10.34
3 Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011 9.10
4 Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008 6.76
5 Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012 6.61
6 Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 2007 5.68
7 Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet 2012 4.27
8 SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 2009 3.55
9 Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 2011 3.01
10 The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013 2.65
11 Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009 2.60
12 The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008 2.42
13 PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005 2.40
14 Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol 2005 2.40
15 A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 2013 2.32
16 Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005 2.28
17 Olfactory dysfunction: common in later life and early warning of neurodegenerative disease. Dtsch Arztebl Int 2013 2.22
18 Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 2013 2.22
19 Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene. Ann Neurol 2009 2.21
20 Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology 2012 2.18
21 Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord 2008 2.15
22 Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 2009 2.09
23 Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 2008 2.04
24 Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 2007 1.94
25 Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain 2005 1.85
26 Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol 2013 1.82
27 Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol 2008 1.79
28 DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med 2009 1.78
29 Red flags for multiple system atrophy. Mov Disord 2008 1.75
30 Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet 2011 1.70
31 PARK6-linked parkinsonism occurs in several European families. Ann Neurol 2002 1.68
32 Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum Mol Genet 2012 1.68
33 Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011 1.66
34 Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord 2014 1.63
35 Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurol 2011 1.62
36 GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest 2008 1.60
37 Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum Mol Genet 2009 1.59
38 Kick and rush: paradoxical kinesia in Parkinson disease. Neurology 2008 1.59
39 Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 2006 1.56
40 UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol 2004 1.54
41 Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord 2005 1.54
42 GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology 2012 1.51
43 VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002 1.48
44 SNCA: major genetic modifier of age at onset of Parkinson's disease. Mov Disord 2013 1.48
45 Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol 2011 1.45
46 Complex relationship between Parkin mutations and Parkinson disease. Am J Med Genet 2002 1.44
47 How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 2003 1.44
48 Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J Neurochem 2009 1.42
49 The effect of increased maximum power output on perioperative and early postoperative outcome in photoselective vaporization of the prostate. Lasers Surg Med 2012 1.41
50 Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor. Neurology 2012 1.41
51 E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004 1.40
52 Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2008 1.39
53 The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted. Eur J Hum Genet 2003 1.36
54 Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010 1.34
55 Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 2007 1.34
56 Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol 2002 1.33
57 NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging 2014 1.32
58 The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 2003 1.30
59 Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord 2012 1.28
60 [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2007 1.24
61 The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol 2007 1.21
62 Genes associated with Parkinson syndrome. J Neurol 2008 1.21
63 Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 2010 1.18
64 Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling. PLoS One 2013 1.18
65 Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol 2011 1.15
66 Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 2002 1.14
67 ATP13A2 variants in early-onset Parkinson's disease patients and controls. Mov Disord 2009 1.12
68 Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 2004 1.12
69 Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk. JAMA Neurol 2013 1.09
70 The transcription factor PITX3 is associated with sporadic Parkinson's disease. Neurobiol Aging 2007 1.09
71 Common variants of LRRK2 are not associated with sporadic Parkinson's disease. Ann Neurol 2005 1.08
72 Inherited myoclonus-dystonia. Adv Neurol 2004 1.08
73 Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis 2009 1.06
74 The role of inflammation in sporadic and familial Parkinson's disease. Cell Mol Life Sci 2013 1.05
75 Analysis of differential DNA damage in the mitochondrial genome employing a semi-long run real-time PCR approach. Nucleic Acids Res 2009 1.05
76 Ataxia with ophthalmoplegia or sensory neuropathy is frequently caused by POLG mutations. Neurology 2009 1.04
77 Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis 2006 1.03
78 Navigated transcranial magnetic stimulation and functional magnetic resonance imaging: advanced adjuncts in preoperative planning for central region tumors. Neurosurgery 2011 1.03
79 Analysis of intrathecal interleukin-6 as a potential predictive factor for vasospasm in subarachnoid hemorrhage. Neurosurgery 2007 1.03
80 Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal 2010 1.01
81 TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Am J Pathol 2004 1.00
82 LINGO1 is not associated with Parkinson's disease in German patients. Am J Med Genet B Neuropsychiatr Genet 2010 0.99
83 HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 2003 0.99
84 GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord 2014 0.99
85 Clinical differentiation of genetically proven benign hereditary chorea and myoclonus-dystonia. Mov Disord 2007 0.99
86 Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Ann Neurol 2002 0.99
87 Delta-like 1 participates in the specification of ventral midbrain progenitor derived dopaminergic neurons. J Neurochem 2007 0.98
88 Spheno-orbital meningiomas: interdisciplinary surgical approach, resectability and long-term results. J Craniomaxillofac Surg 2005 0.98
89 Reduction of susceptibility-induced signal losses in multi-gradient-echo images: application to improved visualization of the subthalamic nucleus. Neuroimage 2009 0.98
90 Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). Arch Neurol 2011 0.97
91 NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis. Hum Mol Genet 2012 0.97
92 Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis. J Neurol 2009 0.96
93 Radicular and nonradicular back pain in Parkinson's disease: a controlled study. Mov Disord 2007 0.96
94 Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease. Neurogenetics 2007 0.96
95 Spontaneous cerebellar hemorrhage--experience with 57 surgically treated patients and review of the literature. Neurosurg Rev 2010 0.95
96 A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiol Aging 2009 0.95
97 The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. Parkinsonism Relat Disord 2005 0.95
98 Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis 2011 0.94
99 High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol 2003 0.94
100 Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism Relat Disord 2008 0.94
101 A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Hum Mol Genet 2012 0.93
102 Intramedullary spinal cord cavernous malformations: clinical features and risk of hemorrhage. Neurosurg Rev 2003 0.92
103 Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. Mov Disord 2010 0.92
104 PARK11 is not linked with Parkinson's disease in European families. Eur J Hum Genet 2005 0.92
105 Polygenic risk of Parkinson disease is correlated with disease age at onset. Ann Neurol 2015 0.92
106 A large genome scan for rare CNVs in amyotrophic lateral sclerosis. Hum Mol Genet 2010 0.92
107 Low field intraoperative MRI-guided surgery of gliomas: a single center experience. Clin Neurol Neurosurg 2009 0.91
108 Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration. Neurobiol Dis 2013 0.91
109 Feasibility of Polestar N20, an ultra-low-field intraoperative magnetic resonance imaging system in resection control of pituitary macroadenomas: lessons learned from the first 40 cases. Neurosurgery 2008 0.91
110 Apolipoprotein E4 is probably responsible for the chromosome 19 linkage peak for Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2005 0.91
111 Predictive value of transcranial sonography in the diagnosis of Parkinson's disease. Mov Disord 2006 0.91
112 A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J Med Genet 2012 0.90
113 A novel mutation in LRSAM1 causes axonal Charcot-Marie-Tooth disease with dominant inheritance. BMC Neurol 2014 0.90
114 Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. PLoS One 2013 0.90
115 Genetic basis of Parkinson's disease: inheritance, penetrance, and expression. Appl Clin Genet 2011 0.90
116 Genetic comorbidities in Parkinson's disease. Hum Mol Genet 2013 0.89
117 Characterization of peripheral hematopoietic stem cells and monocytes in Parkinson's disease. Mov Disord 2013 0.89
118 Use of support vector machines for disease risk prediction in genome-wide association studies: concerns and opportunities. Hum Mutat 2012 0.89
119 A rare truncating mutation in ADH1C (G78Stop) shows significant association with Parkinson disease in a large international sample. Arch Neurol 2005 0.89
120 Kick and rush: paradoxical kinesia in Parkinson disease. Neurology 2009 0.89
121 High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol 2005 0.88
122 Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 2011 0.88
123 Complete reversal of paraplegia after thoracic endovascular aortic repair in a patient with complicated acute aortic dissection using immediate cerebrospinal fluid drainage. Clin Res Cardiol 2009 0.88
124 Myoclonus-dystonia due to genomic deletions in the epsilon-sarcoglycan gene. Ann Neurol 2005 0.88
125 The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. J Alzheimers Dis 2010 0.87
126 DYT7 gene locus for cervical dystonia on chromosome 18p is questionable. Mov Disord 2012 0.87
127 A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain 2007 0.87
128 Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2010 0.87
129 Involuntary eyelid closure after STN-DBS: evidence for different pathophysiological entities. J Neurol Neurosurg Psychiatry 2010 0.87
130 Influence of iMRI-guidance on the extent of resection and survival of patients with glioblastoma multiforme. Technol Cancer Res Treat 2010 0.86
131 High-throughput tissue microarray analysis of CMYC amplificationin urinary bladder cancer. Int J Cancer 2005 0.86
132 Creatine supplementation lowers brain glutamate levels in Huntington's disease. J Neurol 2005 0.86
133 Evaluation of hardware-related geometrical distortion in structural MRI at 7 Tesla for image-guided applications in neurosurgery. Acad Radiol 2011 0.86
134 The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol 2007 0.86
135 No evidence of association of FLJ10986 and ITPR2 with ALS in a large German cohort. Neurobiol Aging 2009 0.86
136 The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism. J Neurol Neurosurg Psychiatry 2013 0.86
137 Visual evoked potentials for intraoperative neurophysiologic monitoring using total intravenous anesthesia. J Neurosurg Anesthesiol 2003 0.86
138 Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in Lewy body disease. J Alzheimers Dis 2010 0.86
139 The 80-W KTP GreenLight laser vaporization of the prostate versus transurethral resection of the prostate (TURP): adjusted analysis of 5-year results of a prospective non-randomized bi-center study. Lasers Med Sci 2015 0.85
140 Clinical variability in ataxia-telangiectasia. J Neurol 2015 0.85
141 Vascular endothelial growth factor plasma levels are significantly elevated in patients with cerebral arteriovenous malformations. Cerebrovasc Dis 2005 0.85
142 Genomic deletion size at the epsilon-sarcoglycan locus determines the clinical phenotype. Brain 2007 0.85
143 "Jerky" dystonia in children: spectrum of phenotypes and genetic testing. Mov Disord 2009 0.85
144 Hunting for genes and mutations: it's worth remembering the basics. Neurology 2008 0.85
145 Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values. Neurosurgery 2009 0.85
146 Intrafamilial variability in fragile X-associated tremor/ataxia syndrome. Mov Disord 2006 0.85
147 Instable cervical spine injury in a toddler: technical note. Childs Nerv Syst 2010 0.84
148 Usefulness of intraoperative ultra low-field magnetic resonance imaging in glioma surgery. Neurosurgery 2008 0.84
149 Cooperative genome-wide analysis shows increased homozygosity in early onset Parkinson's disease. PLoS One 2012 0.84
150 Parkinson's disease and dementia: a longitudinal study (DEMPARK). Neuroepidemiology 2011 0.84
151 Improved detection of microbial ureteral stent colonisation by sonication. World J Urol 2010 0.84
152 Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement 2010 0.84
153 Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. PLoS One 2012 0.83
154 Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 2002 0.83
155 New family with paroxysmal exercise-induced dystonia and epilepsy. Mov Disord 2007 0.83
156 Deep-brain-stimulation does not impair deglutition in Parkinson's disease. Parkinsonism Relat Disord 2012 0.83
157 Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. J Neurol 2007 0.83
158 Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease. Neurosci Lett 2003 0.83
159 Surgical treatment of cerebral abscess with the use of a mobile ultralow-field MRI. Neurosurg Rev 2008 0.82
160 Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus. PLoS One 2013 0.82
161 Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation. J Neurol 2008 0.82
162 Fusion of the cerebellar hemispheres ventral to the brainstem: a rare hindbrain-related malformation. Childs Nerv Syst 2004 0.82
163 Association of clusterin gene polymorphisms with late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 2011 0.82
164 Stereotactic biopsy in gliomas guided by 3-tesla 1H-chemical-shift imaging of choline. Stereotact Funct Neurosurg 2008 0.82
165 UCHL-1 gene in multiple system atrophy: a haplotype tagging approach. Mov Disord 2005 0.81
166 Pallidal deep brain stimulation relieves camptocormia in primary dystonia. J Neurol 2013 0.81
167 Combined flow cytometric analysis of surface and intracellular antigens reveals surface molecule markers of human neuropoiesis. PLoS One 2013 0.81
168 Familial carpal tunnel syndrome: further evidence for a genetic contribution. Clin Genet 2006 0.80
169 Integrative pathway-based approach for genome-wide association studies: identification of new pathways for rheumatoid arthritis and type 1 diabetes. PLoS One 2013 0.80
170 Sporadic rapid-onset dystonia-parkinsonism syndrome: failure of bilateral pallidal stimulation. Mov Disord 2005 0.80
171 Long-term follow-up of subthalamic nucleus stimulation in glucocerebrosidase-associated Parkinson's disease. J Neurol 2012 0.80
172 Mutations in CIZ1 are not a major cause for dystonia in Germany. Mov Disord 2015 0.80
173 An interleukin-6 promoter variant is not associated with an increased risk for Alzheimer's disease. Dement Geriatr Cogn Disord 2004 0.80
174 No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiol Dis 2009 0.80
175 Proteasomal inhibition reduces parkin mRNA in PC12 and SH-SY5Y cells. Parkinsonism Relat Disord 2008 0.80
176 A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease. Mov Disord 2007 0.80
177 High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study. Arch Gerontol Geriatr 2005 0.80
178 A unique case of coincidence of early onset Parkinson's disease and multiple sclerosis. Mov Disord 2007 0.80
179 A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. J Neural Transm (Vienna) 2009 0.80
180 PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease. Parkinsonism Relat Disord 2009 0.80
181 Toxic effects of lipid-mediated gene transfer in ventral mesencephalic explant cultures. Basic Clin Pharmacol Toxicol 2006 0.79
182 Genome-wide association study in musician's dystonia: a risk variant at the arylsulfatase G locus? Mov Disord 2013 0.79
183 No evidence for THAP1/DYT6 variants as disease modifiers in DYT1 dystonia. Mov Disord 2011 0.79
184 Sonographic abnormalities of brainstem structures in restless legs syndrome. Sleep Med 2007 0.79
185 Correlation of active contact positions with the electrophysiological and anatomical subdivisions of the subthalamic nucleus in deep brain stimulation. Stereotact Funct Neurosurg 2013 0.79
186 Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors. Dement Geriatr Cogn Disord 2007 0.78
187 Intraoperative microelectrode recording for the delineation of subthalamic nucleus topography in Parkinson's disease. Brain Stimul 2011 0.78
188 Reverse sensory geste in cervical dystonia. Mov Disord 2009 0.78
189 In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 α-synuclein antibody. Acta Neuropathol 2014 0.78
190 Clozapine serum concentrations in dopamimetic psychosis in Parkinson's disease and related disorders. Eur J Clin Pharmacol 2014 0.78
191 Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Mov Disord 2010 0.78
192 Intraoperative neurophysiological monitoring in an open low-field magnetic resonance imaging system: clinical experience and technical considerations. Neurosurgery 2008 0.78
193 Parkinson's disease: is it all in the genes? Mov Disord 2013 0.78
194 Point mutations in exon 1 of the NR4A2 gene are not a major cause of familial Parkinson's disease. Neurogenetics 2003 0.78
195 Lack of association between the interleukin-1 alpha (-889) polymorphism and early-onset Parkinson's disease. Neurosci Lett 2004 0.77
196 Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's disease. Curr Alzheimer Res 2011 0.77
197 Diurnal variation of hypothalamic function and chronic subthalamic nucleus stimulation in Parkinson's disease. Neuroendocrinology 2012 0.77
198 Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. Neurobiol Aging 2011 0.77
199 Low field intraoperative MRI in glioma surgery. Acta Neurochir Suppl 2011 0.77
200 Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2. Glia 2014 0.77
201 Meta analysis of whole-genome linkage scans with data uncertainty: an application to Parkinson's disease. BMC Genet 2007 0.77
202 Data protection in biomaterial banks for Parkinson's disease research: the model of GEPARD (Gene Bank Parkinson's Disease Germany). Mov Disord 2007 0.77
203 A standardised evaluation of pre-surgical imaging of the corticospinal tract: where to place the seed ROI. Neurosurg Rev 2009 0.77
204 Microbial colonization and ureteral stent-associated storage lower urinary tract symptoms: the forgotten piece of the puzzle? World J Urol 2012 0.77
205 Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer's disease. Neurosci Lett 2006 0.77
206 Intraoperative magnetic resonance imaging in the surgical treatment of cerebral metastases. J Surg Oncol 2010 0.76
207 Acupuncture-related modulation of pain-associated brain networks during electrical pain stimulation: a functional magnetic resonance imaging study. J Altern Complement Med 2014 0.76
208 GreenLight laser vs diode laser vaporization of the prostate: 3-year results of a prospective nonrandomized study. J Endourol 2014 0.76
209 The variable phenotype of FXTAS: a common cause of "idiopathic" disorders. Neurology 2005 0.76
210 The human sideroflexin 5 (SFXN5) gene: sequence, expression analysis and exclusion as a candidate for PARK3. Gene 2002 0.76
211 New aspects of genetic contributions to Parkinson's disease. J Mol Neurosci 2004 0.76
212 Mutations in the pantothenate kinase gene PANK2 are not associated with Parkinson disease. Neurosci Lett 2005 0.76
213 Periphilin is a novel interactor of synphilin-1, a protein implicated in Parkinson's disease. Neurogenetics 2010 0.76
214 Usefulness of Genetic Testing in PD and PD Trials: A Balanced Review. J Parkinsons Dis 2015 0.76
215 Feasibility of intraoperative MRI guidance for craniotomy and tumor resection in the semisitting position. J Neurosurg Anesthesiol 2011 0.76
216 Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson's disease families. Neurosci Lett 2007 0.76
217 Glioma extent of resection and ultra-low-field iMRI: interim analysis of a prospective randomized trial. Acta Neurochir Suppl 2011 0.75
218 LRRK2: Understanding the role of common and rare variants in Parkinson's disease. Mov Disord 2012 0.75
219 The differential diagnosis and treatment of tremor. Dtsch Arztebl Int 2014 0.75
220 In reply. Dtsch Arztebl Int 2013 0.75
221 No association between polymorphisms in the glutamate transporter SLC1A2 and Parkinson's disease. Mov Disord 2013 0.75
222 Nutrition and the risk for Parkinson's disease: review of the literature. J Neural Transm (Vienna) 2008 0.75
223 Lipid-mediated glial cell line-derived neurotrophic factor gene transfer to cultured porcine ventral mesencephalic tissue. Exp Neurol 2002 0.75
224 Acute parkinsonism with corresponding lesions in the basal ganglia after heroin abuse. Neurology 2007 0.75
225 Personalized Medicine Approaches in Parkinson's Disease: The Genetic Perspective. J Parkinsons Dis 2016 0.75
226 Self estimated quality of life in monogenetic Parkinson's disease. Mov Disord 2010 0.75
227 No association between NOD2 variants and Parkinson's disease. Mov Disord 2012 0.75
228 Implementation of the ultra low field intraoperative MRI PoleStar N20 during resection control of pituitary adenomas. Acta Neurochir Suppl 2011 0.75
229 Further delineation of the association signal on chromosome 5 from the first whole genome association study in Parkinson's disease. Neurobiol Aging 2008 0.75
230 Severe muscular fasciculations as an uncommon side-effect due to microdefect of an extension wire in deep brain stimulation. Mov Disord 2009 0.75
231 Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication. Mov Disord 2006 0.75
232 Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia. Neurodegener Dis 2016 0.75
233 Genetic testing in neurological diseases. J Neurol 2012 0.75
234 Quantification of oxygen fluxes in a long gravity sewer. Water Res 2004 0.75
235 Favourable outcome after biopsy and decompression of a holocord intramedullary spinal cord astrocytoma in a newborn. Eur J Paediatr Neurol 2002 0.75
236 Epsilon-sarcoglycan is not involved in sporadic Gilles de la Tourette syndrome. Neurogenetics 2005 0.75
237 Parkinson's syndrome in a young patient with Klinefelter's syndrome--a case report. Mov Disord 2008 0.75